New Zealand markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
13.20-0.08 (-0.60%)
At close: 04:00PM EDT
13.20 0.00 (0.00%)
After hours: 06:14PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 41.46B
Enterprise value 69.41B
Trailing P/E 45.11
Forward P/E 112.36
PEG ratio (5-yr expected) 3.80
Price/sales (ttm)1.52
Price/book (mrq)0.89
Enterprise value/revenue 2.55
Enterprise value/EBITDA 10.85

Trading information

Stock price history

Beta (5Y monthly) 0.54
52-week change 3-18.77%
S&P500 52-week change 329.31%
52-week high 316.39
52-week low 312.77
50-day moving average 313.59
200-day moving average 314.40

Share statistics

Avg vol (3-month) 31.62M
Avg vol (10-day) 31.46M
Shares outstanding 53.14B
Implied shares outstanding 63.14B
Float 81.55B
% held by insiders 10.00%
% held by institutions 12.51%
Shares short (30 Apr 2024) 45.97M
Short ratio (30 Apr 2024) 43.71
Short % of float (30 Apr 2024) 4N/A
Short % of shares outstanding (30 Apr 2024) 40.20%
Shares short (prior month 28 Mar 2024) 48.12M

Dividends & splits

Forward annual dividend rate 40.64
Forward annual dividend yield 44.83%
Trailing annual dividend rate 3188.00
Trailing annual dividend yield 31,415.66%
5-year average dividend yield 44.73
Payout ratio 4104.57%
Dividend date 311 Dec 2023
Ex-dividend date 428 Sept 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024


Profit margin 3.38%
Operating margin (ttm)-7.40%

Management effectiveness

Return on assets (ttm)1.57%
Return on equity (ttm)2.12%

Income statement

Revenue (ttm)4.26T
Revenue per share (ttm)1,362.70
Quarterly revenue growth (yoy)9.90%
Gross profit (ttm)N/A
Net income avi to common (ttm)144.07B
Diluted EPS (ttm)0.29
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)457.8B
Total cash per share (mrq)291.78
Total debt (mrq)5.53T
Total debt/equity (mrq)76.05%
Current ratio (mrq)1.11
Book value per share (mrq)4,635.56

Cash flow statement

Operating cash flow (ttm)716.34B
Levered free cash flow (ttm)35.08B